Our target range is 20 to 80 base pairs
A defined range lets us compare one batch with the next.
Our target range for PDRN is 20 to 80 base pairs. The PDRN in the literature commonly spans a far wider range.
A defined range means we can characterise a batch and compare it with another. We lay two batches made months apart side by side and check that the fragments fall where they should.
We extract the DNA, purify it and bring it to the range, and we have developed our own method for each of the three steps. The last step makes the range, and the first two decide whether it can be made cleanly. Plant cells are among the hardest biological sources to open.
None of this establishes what the material does in people. Our most advanced programme is preclinical, and no Synthena medicine has been approved for any indication.
About Synthena Pharmaceuticals
Synthena Pharmaceuticals is a pharmaceutical company founded in Hong Kong in July 2026 and focused on one substance, PDRN. Its aim is to turn PDRN into medicines made without animal-derived sources, produced within a defined fragment-length range and studied across five fields of human biology. Its most advanced programme is preclinical; no Synthena medicine has entered clinical trials or been approved for any indication.
This page describes research and development. It does not establish the safety or efficacy of any Synthena medicine.
